Compare ESQ & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | CDNA |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 1.1B |
| IPO Year | 2017 | 2007 |
| Metric | ESQ | CDNA |
|---|---|---|
| Price | $111.89 | $21.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $120.33 | $28.00 |
| AVG Volume (30 Days) | 83.8K | ★ 652.5K |
| Earning Date | 04-23-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $35.15 | $16.01 |
| Revenue Next Year | $39.09 | $11.31 |
| P/E Ratio | ★ $79.64 | $429.80 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $87.54 | $10.96 |
| 52 Week High | $119.86 | $23.24 |
| Indicator | ESQ | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 59.06 |
| Support Level | $103.31 | $15.80 |
| Resistance Level | $116.59 | $22.89 |
| Average True Range (ATR) | 2.64 | 1.00 |
| MACD | 0.72 | -0.06 |
| Stochastic Oscillator | 84.05 | 76.54 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.